Skip to main content
Erschienen in: Wiener Medizinische Wochenschrift 11-12/2015

01.06.2015 | main topic

Phytopharmaceutical treatment of anxiety, depression, and dementia in the elderly: evidence from randomized, controlled clinical trials

verfasst von: O. Univ. Prof. Dr. h.c.mult. Dr.med. Siegfried Kasper

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 11-12/2015

Einloggen, um Zugang zu erhalten

Summary

Based on subgroup analyses of randomized, controlled clinical trials, we review the efficacy of three phytopharmaceutical drugs, respectively of the corresponding active substances silexan® (WS® 1265, lavender oil) in anxiety disorders, WS® 5570 (Hypericum extract) in major depression, and EGb 761® (Ginkgo biloba extract) in Alzheimer, vascular, or mixed type dementia, in elderly patients aged ≥ 60 years.
Four trials were eligible in each indication. Meta-analyses and analyses based on pooled raw data showed that the three drugs were significantly superior to placebo in the elderly subset, and that their treatment effects reflected in the main outcome measures (Hamilton Anxiety scale, Hamilton Depression scale, Neuropsychiatric Inventory) were comparable with those observed in the original trials without age restrictions.
The results confirm the efficacy of the three herbal active substances in elderly patients of ≥ 60 years of age. In anxiety, depression, and dementia, they thus represent efficacious and well-tolerated alternatives to synthetic drugs.
Fußnoten
1
Silexan® (WS® 1265) is the active substance of Lasea®(Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany).
 
2
WS® 5570 is the active substance of Neuroplant® (Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany).
 
3
EGb 761®is the active substance of Tebonin® (Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany).
 
Literatur
1.
Zurück zum Zitat European Commission. The 2015 Ageing Report: underlying assumptions and projection methodologies. In: European Economy. Brussels: European Commission (DG ECFIN) and the Economic Policy Committee (AWG); 2014. European Commission. The 2015 Ageing Report: underlying assumptions and projection methodologies. In: European Economy. Brussels: European Commission (DG ECFIN) and the Economic Policy Committee (AWG); 2014.
2.
Zurück zum Zitat Zimmermann T, Kaduszkiewicz H, van den Bussche H, et al. Potenziell inadaquate Medikamente bei alteren hausarztlich versorgten Patientinnen und Patienten: Eine retrospektive Langsschnittanalyse. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013;56:941–9.PubMedCrossRef Zimmermann T, Kaduszkiewicz H, van den Bussche H, et al. Potenziell inadaquate Medikamente bei alteren hausarztlich versorgten Patientinnen und Patienten: Eine retrospektive Langsschnittanalyse. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013;56:941–9.PubMedCrossRef
3.
Zurück zum Zitat Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57:6–14.PubMedCentralPubMedCrossRef Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57:6–14.PubMedCentralPubMedCrossRef
4.
Zurück zum Zitat Goldberg RM, Mabee J, Chan L, et al. Drug-drug and drug-disease interactions in the ED: analysis of a high-risk population. Am J Emerg Med. 1996;14:447–50.PubMedCrossRef Goldberg RM, Mabee J, Chan L, et al. Drug-drug and drug-disease interactions in the ED: analysis of a high-risk population. Am J Emerg Med. 1996;14:447–50.PubMedCrossRef
5.
Zurück zum Zitat Nishtala PS, Salahudeen MS. Temporal trends in polypharmacy and hyperpolypharmacy in older New Zealanders over a 9-year period: 2005–2013. Gerontology. 2014. doi:10.1159/000368191. Nishtala PS, Salahudeen MS. Temporal trends in polypharmacy and hyperpolypharmacy in older New Zealanders over a 9-year period: 2005–2013. Gerontology. 2014. doi:10.1159/000368191.
6.
Zurück zum Zitat Pfortmueller CA, Lindner G, Exadaktylos AK. Reducing fall risk in the elderly: risk factors and fall prevention, a systematic review. Minerva Med. 2014;105:275–81.PubMed Pfortmueller CA, Lindner G, Exadaktylos AK. Reducing fall risk in the elderly: risk factors and fall prevention, a systematic review. Minerva Med. 2014;105:275–81.PubMed
7.
Zurück zum Zitat Richardson K, Bennett K, Kenny RA. Polypharmacy including falls risk-increasing medications and subsequent falls in community-dwelling middle-aged and older adults. Age Ageing. 2015;44:90–6.PubMedCrossRef Richardson K, Bennett K, Kenny RA. Polypharmacy including falls risk-increasing medications and subsequent falls in community-dwelling middle-aged and older adults. Age Ageing. 2015;44:90–6.PubMedCrossRef
8.
Zurück zum Zitat Hein C, Forgues A, Piau A, et al. Impact of polypharmacy on occurrence of delirium in elderly emergency patients. J Am Med Dir Assoc. 2014;15:850e11–5.PubMedCrossRef Hein C, Forgues A, Piau A, et al. Impact of polypharmacy on occurrence of delirium in elderly emergency patients. J Am Med Dir Assoc. 2014;15:850e11–5.PubMedCrossRef
9.
Zurück zum Zitat Leiss W, Mean M, Limacher A, et al. Polypharmacy is associated with an increased risk of bleeding in elderly patients with venous thromboembolism. J Gen Intern Med. 2015;30:17–24.PubMedCrossRef Leiss W, Mean M, Limacher A, et al. Polypharmacy is associated with an increased risk of bleeding in elderly patients with venous thromboembolism. J Gen Intern Med. 2015;30:17–24.PubMedCrossRef
10.
Zurück zum Zitat Polypharmazie TPA. Treiben Sie den Teufel nicht mit dem Beelzebub aus. MMW Fortschr Med. 2014;156:56–61 (quiz 2). Polypharmazie TPA. Treiben Sie den Teufel nicht mit dem Beelzebub aus. MMW Fortschr Med. 2014;156:56–61 (quiz 2).
11.
Zurück zum Zitat Gómez C, Vega-Quiroga S, Bermejo-Pareja F, et al. Polypharmacy in the elderly: a marker of increased risk of mortality in a population-based prospective study (NEDICES). Gerontology. 2014. doi:10.1159/000365328. Gómez C, Vega-Quiroga S, Bermejo-Pareja F, et al. Polypharmacy in the elderly: a marker of increased risk of mortality in a population-based prospective study (NEDICES). Gerontology. 2014. doi:10.1159/000365328.
12.
Zurück zum Zitat Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014;13:57–65.PubMedCrossRef Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014;13:57–65.PubMedCrossRef
13.
Zurück zum Zitat Wickop B, Langebrake C. Gute Verordnungspraxis bei älteren Patienten. Ther Umsch. 2014;71:366–73.PubMedCrossRef Wickop B, Langebrake C. Gute Verordnungspraxis bei älteren Patienten. Ther Umsch. 2014;71:366–73.PubMedCrossRef
14.
Zurück zum Zitat Loew D. Pflanzliche versus synthetische Arzneimittel in der Geriatrie—eine Betrachtung zur Arzneimittelsicherheit aus pharmakologischer und pharmakokinetischer Sicht. Ars Medici Thema Phytotherapie. 2012:15–20. Loew D. Pflanzliche versus synthetische Arzneimittel in der Geriatrie—eine Betrachtung zur Arzneimittelsicherheit aus pharmakologischer und pharmakokinetischer Sicht. Ars Medici Thema Phytotherapie. 2012:15–20.
15.
Zurück zum Zitat Loew D, Beer AM, Adler M. Phytotherapie in der Praxis: Einsatzmöglichkeiten bei geriatrischen Erkrankungen. Z Phytother. 2010;31:145–8.CrossRef Loew D, Beer AM, Adler M. Phytotherapie in der Praxis: Einsatzmöglichkeiten bei geriatrischen Erkrankungen. Z Phytother. 2010;31:145–8.CrossRef
16.
Zurück zum Zitat Sami MB, Nilforooshan R. The natural course of anxiety disorders in the elderly: a systematic review of longitudinal trials. Int Psychogeriatr. 2014. doi:10.1017/S1041610214001847. Sami MB, Nilforooshan R. The natural course of anxiety disorders in the elderly: a systematic review of longitudinal trials. Int Psychogeriatr. 2014. doi:10.1017/S1041610214001847.
17.
Zurück zum Zitat Bandelow B, Sher L, Bunevicius R, et al. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int J Psychiatry Clin Pract. 2012;16:77–84.PubMedCrossRef Bandelow B, Sher L, Bunevicius R, et al. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int J Psychiatry Clin Pract. 2012;16:77–84.PubMedCrossRef
18.
Zurück zum Zitat Council of Europe. European Pharmacopoeia. 8th ed. Strasbourg: Council of Europe; 2015. Council of Europe. European Pharmacopoeia. 8th ed. Strasbourg: Council of Europe; 2015.
19.
Zurück zum Zitat Schuwald AM, Nöldner M, Wilmes T, et al. Lavender oil-potent anxiolytic properties via modulating voltage dependent calcium channels. PloS one. 2013;8:e59998.PubMedCentralPubMedCrossRef Schuwald AM, Nöldner M, Wilmes T, et al. Lavender oil-potent anxiolytic properties via modulating voltage dependent calcium channels. PloS one. 2013;8:e59998.PubMedCentralPubMedCrossRef
20.
Zurück zum Zitat Baldinger P, Hoflich AS, Mitterhauser M, et al. Effects of Silexan on the serotonin-1 A receptor and microstructure of the human brain: a randomized, placebo-controlled, double-blind, cross-over study with molecular and structural neuroimaging. Int J Neuropsychopharmacol. 2014. doi:10.1093/ijnp/pyu063. Baldinger P, Hoflich AS, Mitterhauser M, et al. Effects of Silexan on the serotonin-1 A receptor and microstructure of the human brain: a randomized, placebo-controlled, double-blind, cross-over study with molecular and structural neuroimaging. Int J Neuropsychopharmacol. 2014. doi:10.1093/ijnp/pyu063.
21.
Zurück zum Zitat Kasper S. An orally administered lavandula oil preparation (Silexan) for anxiety disorder and related conditions: an evidence based review. Int J Psychiatry ClinPract. 2013;17(Suppl. 1):15–22.CrossRef Kasper S. An orally administered lavandula oil preparation (Silexan) for anxiety disorder and related conditions: an evidence based review. Int J Psychiatry ClinPract. 2013;17(Suppl. 1):15–22.CrossRef
22.
Zurück zum Zitat Kasper S, Gastpar M, Müller WE, et al. Silexan, an orally administered Lavandula oil preparation, is effective in the treatment of ‘subsyndromal’ anxiety disorder: a randomized, double-blind, placebo controlled trial. Int Clin Psychopharmacol. 2010;25:277–87.PubMedCrossRef Kasper S, Gastpar M, Müller WE, et al. Silexan, an orally administered Lavandula oil preparation, is effective in the treatment of ‘subsyndromal’ anxiety disorder: a randomized, double-blind, placebo controlled trial. Int Clin Psychopharmacol. 2010;25:277–87.PubMedCrossRef
23.
Zurück zum Zitat Kasper S, Gastpar M, Müller WE, et al. Lavender oil preparation Silexan is effective in generalized anxiety disorder—a randomized, double-blind comparison to placebo and paroxetine. Int J Neuropsychopharmacolog. 2014;17:859–69.CrossRef Kasper S, Gastpar M, Müller WE, et al. Lavender oil preparation Silexan is effective in generalized anxiety disorder—a randomized, double-blind comparison to placebo and paroxetine. Int J Neuropsychopharmacolog. 2014;17:859–69.CrossRef
24.
Zurück zum Zitat Woelk H, Schläfke S. A multi-center, double-blind, randomised study of the Lavender oil preparation Silexan in comparison to Lorazepam for generalized anxiety disorder. Phytomedicine. 2010;17:94–9.PubMedCrossRef Woelk H, Schläfke S. A multi-center, double-blind, randomised study of the Lavender oil preparation Silexan in comparison to Lorazepam for generalized anxiety disorder. Phytomedicine. 2010;17:94–9.PubMedCrossRef
25.
Zurück zum Zitat Hamilton M. Hamilton Anxiety Scale (HAMA). In: Guy W, editor, ECDEU assessment manual for psychopharmacology. Rockville: U.S. National Institute of Health, Psychopharmacology Research Branch; 1976.pp 193–7. Hamilton M. Hamilton Anxiety Scale (HAMA). In: Guy W, editor, ECDEU assessment manual for psychopharmacology. Rockville: U.S. National Institute of Health, Psychopharmacology Research Branch; 1976.pp 193–7.
26.
Zurück zum Zitat Kasper S, Anghelescu I, Dienel A. Efficacy of Silexan (WS® 1265) in patients with restlessness and sleep disturbance. In: Annual Congress of the German Society for Psychiatry and Psychotherapy (DGPPN). Berlin, Germany; 2010. Kasper S, Anghelescu I, Dienel A. Efficacy of Silexan (WS® 1265) in patients with restlessness and sleep disturbance. In: Annual Congress of the German Society for Psychiatry and Psychotherapy (DGPPN). Berlin, Germany; 2010.
27.
Zurück zum Zitat National Institute of Mental Health. 12– CGI. Clinical Global Impressions. In: Guy W, editor, EDCEU Assessment in Psychopharmacology. Rockville: U.S. National Institute of Mental Health, Psychopharmacology Research Branch; 1970. pp 217–22. National Institute of Mental Health. 12– CGI. Clinical Global Impressions. In: Guy W, editor, EDCEU Assessment in Psychopharmacology. Rockville: U.S. National Institute of Mental Health, Psychopharmacology Research Branch; 1970. pp 217–22.
28.
Zurück zum Zitat Djernes JK. Prevalence and predictors of depression in populations of elderly: a review. Acta Psychiatr Scand. 2006;113:372–87.PubMedCrossRef Djernes JK. Prevalence and predictors of depression in populations of elderly: a review. Acta Psychiatr Scand. 2006;113:372–87.PubMedCrossRef
30.
Zurück zum Zitat Helmchen H, Linden M, Wernicke T. Psychiatrische Morbidität bei Hochbetagten. Ergebnisseaus der Berliner Altersstudie. Nervenarzt. 1996;67:739–50.PubMedCrossRef Helmchen H, Linden M, Wernicke T. Psychiatrische Morbidität bei Hochbetagten. Ergebnisseaus der Berliner Altersstudie. Nervenarzt. 1996;67:739–50.PubMedCrossRef
31.
Zurück zum Zitat Linden M, Kurtz G, Baltes MM, et al. Depression bei Hochbetagten. Ergebnisse der Berliner Altersstudie. Nervenarzt. 1998;69:27–37.PubMedCrossRef Linden M, Kurtz G, Baltes MM, et al. Depression bei Hochbetagten. Ergebnisse der Berliner Altersstudie. Nervenarzt. 1998;69:27–37.PubMedCrossRef
32.
Zurück zum Zitat Coupland C, Dhiman P, Morriss R, et al. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ. 2011;343:d4551.PubMedCentralPubMedCrossRef Coupland C, Dhiman P, Morriss R, et al. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ. 2011;343:d4551.PubMedCentralPubMedCrossRef
33.
Zurück zum Zitat Bauer M, Pfennig A, Severus E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. World J Biol Psychiatry. 2013;14:334–85.PubMedCrossRef Bauer M, Pfennig A, Severus E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. World J Biol Psychiatry. 2013;14:334–85.PubMedCrossRef
34.
Zurück zum Zitat Müller WE. Current St John’s wort research from mode of action to clinical efficacy. Pharmacol Res. 2003;47:101–9.PubMedCrossRef Müller WE. Current St John’s wort research from mode of action to clinical efficacy. Pharmacol Res. 2003;47:101–9.PubMedCrossRef
35.
Zurück zum Zitat Wurglics M, Westerhoff K, Kaunzinger A, et al. Comparison of German St. John’s wort products according to hyperforin and total hypericin content. J Am Pharm Assoc (Wash). 2001;41:560–6. Wurglics M, Westerhoff K, Kaunzinger A, et al. Comparison of German St. John’s wort products according to hyperforin and total hypericin content. J Am Pharm Assoc (Wash). 2001;41:560–6.
36.
Zurück zum Zitat Gastpar M. Hypericum extract WS (R) 5570 for depression—an overview. Int J Psychiatry Clin Pract. 2013;17(Suppl. 1):1–7.PubMedCrossRef Gastpar M. Hypericum extract WS (R) 5570 for depression—an overview. Int J Psychiatry Clin Pract. 2013;17(Suppl. 1):1–7.PubMedCrossRef
37.
Zurück zum Zitat Kasper S, Gastpar M, Müller WE, et al. Efficacy of St. John’s wort extract WS 5570 in acute treatment of mild depression: a reanalysis of data from controlled clinical trials. Eur Arch Psychiatry Clin Neurosci. 2008;258:59–63.PubMedCrossRef Kasper S, Gastpar M, Müller WE, et al. Efficacy of St. John’s wort extract WS 5570 in acute treatment of mild depression: a reanalysis of data from controlled clinical trials. Eur Arch Psychiatry Clin Neurosci. 2008;258:59–63.PubMedCrossRef
38.
Zurück zum Zitat Kasper S, Gastpar M, Möller HJ, et al. Better tolerability of St. John’s wort extract WS 5570 compared to treatment with SSRIs: a reanalysis of data from controlled clinical trials in acute major depression. Int Clin Psychopharmacol. 2010;25:204–13.PubMedCrossRef Kasper S, Gastpar M, Möller HJ, et al. Better tolerability of St. John’s wort extract WS 5570 compared to treatment with SSRIs: a reanalysis of data from controlled clinical trials in acute major depression. Int Clin Psychopharmacol. 2010;25:204–13.PubMedCrossRef
39.
Zurück zum Zitat Linde K. St.John’s wort—an overview. Forsch Komplementarmed. 2009;16:146–55.CrossRef Linde K. St.John’s wort—an overview. Forsch Komplementarmed. 2009;16:146–55.CrossRef
40.
Zurück zum Zitat Borrelli F, Izzo AA. Herb-drug interactions with St John’s wort (Hypericumperforatum): an update on clinical observations. AAPS J. 2009;11:710–27.PubMedCentralPubMedCrossRef Borrelli F, Izzo AA. Herb-drug interactions with St John’s wort (Hypericumperforatum): an update on clinical observations. AAPS J. 2009;11:710–27.PubMedCentralPubMedCrossRef
41.
Zurück zum Zitat Lecrubier Y, Clerc G, Didi R, et al. Efficacy of St. John’s wort extract WS 5570 in major depression: a double-blind, placebo-controlled trial. Am J Psychiatry. 2002;159:1361–6.PubMedCrossRef Lecrubier Y, Clerc G, Didi R, et al. Efficacy of St. John’s wort extract WS 5570 in major depression: a double-blind, placebo-controlled trial. Am J Psychiatry. 2002;159:1361–6.PubMedCrossRef
42.
Zurück zum Zitat Kasper S, Anghelescu I, Szegedi A, et al. Superior efficacy of St John’s wort extract WS® 5570 compared to placebo in patients with major depression: a randomized, double-blind, placebo-controlled, multi-center trial. BMC Med. 2006. doi:10.1186/1741-7015-4-14. Kasper S, Anghelescu I, Szegedi A, et al. Superior efficacy of St John’s wort extract WS® 5570 compared to placebo in patients with major depression: a randomized, double-blind, placebo-controlled, multi-center trial. BMC Med. 2006. doi:10.1186/1741-7015-4-14.
43.
Zurück zum Zitat Szegedi A, Kohnen R, Dienel A, et al. Acute treatment of moderate to severe depression with hypericum extract WS 5570 (St John’s wort): randomised controlled double blind non-inferiority trial versus paroxetine. BMJ. 2005;330:503–6.PubMedCentralPubMedCrossRef Szegedi A, Kohnen R, Dienel A, et al. Acute treatment of moderate to severe depression with hypericum extract WS 5570 (St John’s wort): randomised controlled double blind non-inferiority trial versus paroxetine. BMJ. 2005;330:503–6.PubMedCentralPubMedCrossRef
44.
Zurück zum Zitat Kasper S, Volz HP, Möller HJ, et al. Continuation and long-term maintenance treatment with Hypericum extract WS 5570 after recovery from an acute episode of moderate depression—a double-blind, randomized, placebo controlled long-term trial. Eur Neuropsychopharmacol. 2008;18:803–13.PubMedCrossRef Kasper S, Volz HP, Möller HJ, et al. Continuation and long-term maintenance treatment with Hypericum extract WS 5570 after recovery from an acute episode of moderate depression—a double-blind, randomized, placebo controlled long-term trial. Eur Neuropsychopharmacol. 2008;18:803–13.PubMedCrossRef
45.
Zurück zum Zitat Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967;6:278–96.PubMedCrossRef Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967;6:278–96.PubMedCrossRef
46.
Zurück zum Zitat Prince M, Bryce R, Albanese E, et al. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimer’s Dement. 2013;9:63–75 e2.PubMedCrossRef Prince M, Bryce R, Albanese E, et al. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimer’s Dement. 2013;9:63–75 e2.PubMedCrossRef
47.
Zurück zum Zitat Plassman BL, Langa KM, Fisher GG, et al. Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology. 2007;29:125–32.PubMedCentralPubMedCrossRef Plassman BL, Langa KM, Fisher GG, et al. Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology. 2007;29:125–32.PubMedCentralPubMedCrossRef
48.
Zurück zum Zitat Berr C, Wancata J, Ritchie K. Prevalence of dementia in the elderly in Europe. Eur Neuropsychopharmacol. 2005;15:463–71. Berr C, Wancata J, Ritchie K. Prevalence of dementia in the elderly in Europe. Eur Neuropsychopharmacol. 2005;15:463–71.
49.
Zurück zum Zitat Schneider JA, Arvanitakis Z, Bang W, et al. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007;69:2197–204.PubMedCrossRef Schneider JA, Arvanitakis Z, Bang W, et al. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007;69:2197–204.PubMedCrossRef
50.
Zurück zum Zitat Daviglus ML, Bell CC, Berrettini W, et al. National Institutes of Health State-of-the-Science Conference statement: preventing Alzheimer disease and cognitive decline. Ann Intern Med. 2010;153:176–81.PubMedCrossRef Daviglus ML, Bell CC, Berrettini W, et al. National Institutes of Health State-of-the-Science Conference statement: preventing Alzheimer disease and cognitive decline. Ann Intern Med. 2010;153:176–81.PubMedCrossRef
51.
Zurück zum Zitat Luchsinger JA, Reitz C, Honig LS, et al. Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology. 2005;65:545–51.PubMedCentralPubMedCrossRef Luchsinger JA, Reitz C, Honig LS, et al. Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology. 2005;65:545–51.PubMedCentralPubMedCrossRef
52.
Zurück zum Zitat Ihl R, Frölich L, Winblad B, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of Alzheimer’s disease and other dementias. World J Biol Psychiatry. 2011;12:2–32.PubMedCrossRef Ihl R, Frölich L, Winblad B, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of Alzheimer’s disease and other dementias. World J Biol Psychiatry. 2011;12:2–32.PubMedCrossRef
53.
Zurück zum Zitat Abdel-Kader R, Hauptmann S, Keil U, et al. Stabilization of mitochondrial function by Ginkgo biloba extract (EGb 761). Pharmacol Res. 2007;56:493–502.PubMedCrossRef Abdel-Kader R, Hauptmann S, Keil U, et al. Stabilization of mitochondrial function by Ginkgo biloba extract (EGb 761). Pharmacol Res. 2007;56:493–502.PubMedCrossRef
54.
Zurück zum Zitat Költringer P, Langsteger W, Eber O. Dose-dependent hemorheological effects and microcirulatory modifications following intravenous administration of Ginkgo biloba special extract EGb 761. Clin Hemorheol. 1995;15:649–56. Költringer P, Langsteger W, Eber O. Dose-dependent hemorheological effects and microcirulatory modifications following intravenous administration of Ginkgo biloba special extract EGb 761. Clin Hemorheol. 1995;15:649–56.
55.
Zurück zum Zitat Ramassamy C, Longpre F, Christen Y. Ginkgo biloba extract (EGb 761) in Alzheimer’s disease: is there any evidence? Curr Alzheimer Res. 2007;4:253–62.PubMedCrossRef Ramassamy C, Longpre F, Christen Y. Ginkgo biloba extract (EGb 761) in Alzheimer’s disease: is there any evidence? Curr Alzheimer Res. 2007;4:253–62.PubMedCrossRef
56.
Zurück zum Zitat Tchantchou F, Xu Y, Wu Y, et al. EGb 761 enhances adult hippocampal neurogenesis and phosphorylation of CREB in transgenic mouse model of Alzheimer’s disease. FASEB J. 2007;21:2400–8.PubMedCrossRef Tchantchou F, Xu Y, Wu Y, et al. EGb 761 enhances adult hippocampal neurogenesis and phosphorylation of CREB in transgenic mouse model of Alzheimer’s disease. FASEB J. 2007;21:2400–8.PubMedCrossRef
57.
Zurück zum Zitat Wu Y, Wu Z, Butko P, et al. Amyloid-beta-induced pathological behaviors are suppressed by Ginkgo biloba extract EGb 761 and ginkgolides in transgenic Caenorhabditis elegans. J Neurosci. 2006;26:13102–13.PubMedCrossRef Wu Y, Wu Z, Butko P, et al. Amyloid-beta-induced pathological behaviors are suppressed by Ginkgo biloba extract EGb 761 and ginkgolides in transgenic Caenorhabditis elegans. J Neurosci. 2006;26:13102–13.PubMedCrossRef
58.
Zurück zum Zitat Gauthier S, Schlaefke S. Efficacy and tolerability of Ginkgo biloba extract EGb 761(R) in dementia: a systematic review and meta-analysis of randomized placebo-controlled trials. Clin Interv Aging. 2014;9:2065–77.PubMedCentralPubMedCrossRef Gauthier S, Schlaefke S. Efficacy and tolerability of Ginkgo biloba extract EGb 761(R) in dementia: a systematic review and meta-analysis of randomized placebo-controlled trials. Clin Interv Aging. 2014;9:2065–77.PubMedCentralPubMedCrossRef
59.
Zurück zum Zitat Ihl R. Effects of Ginkgo biloba extract EGb 761 (R) in dementia with neuropsychiatric features: review of recently completed randomised, controlled trials. Int J Psychiatry Clin Pract. 2013;17(Suppl. 1):8–14.PubMedCrossRef Ihl R. Effects of Ginkgo biloba extract EGb 761 (R) in dementia with neuropsychiatric features: review of recently completed randomised, controlled trials. Int J Psychiatry Clin Pract. 2013;17(Suppl. 1):8–14.PubMedCrossRef
60.
Zurück zum Zitat Janßen IM, Sturtz S, Skipka G, et al. Ginkgo biloba in Alzheimer’s disease: a systematic review. Wien Med Wochenschr. 2010;160:539–46.PubMedCrossRef Janßen IM, Sturtz S, Skipka G, et al. Ginkgo biloba in Alzheimer’s disease: a systematic review. Wien Med Wochenschr. 2010;160:539–46.PubMedCrossRef
61.
Zurück zum Zitat Tan MS, Yu JT, Tan CC, et al. Efficacy and adverse effects of ginkgo biloba for cognitive impairment and dementia: a systematic review and meta-analysis. J Alzheimers Dis. 2015;43:589–603.PubMed Tan MS, Yu JT, Tan CC, et al. Efficacy and adverse effects of ginkgo biloba for cognitive impairment and dementia: a systematic review and meta-analysis. J Alzheimers Dis. 2015;43:589–603.PubMed
62.
Zurück zum Zitat Yang M, Xu DD, Zhang Y, et al. A systematic review on natural medicines for the prevention and treatment of Alzheimer’s disease with meta-analyses of intervention effect of ginkgo. Am J Chin Med. 2014;42:505–21.PubMedCrossRef Yang M, Xu DD, Zhang Y, et al. A systematic review on natural medicines for the prevention and treatment of Alzheimer’s disease with meta-analyses of intervention effect of ginkgo. Am J Chin Med. 2014;42:505–21.PubMedCrossRef
63.
Zurück zum Zitat Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology. 1997;48:S10–6.PubMedCrossRef Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology. 1997;48:S10–6.PubMedCrossRef
64.
Zurück zum Zitat Herrschaft H, Nacu A, Likhachev S, et al. Ginkgo biloba extract EGb 761(R) in dementia with neuropsychiatric features: a randomised, placebo-controlled trial to confirm the efficacy and safety of a daily dose of 240 mg. J Psychiatr Res. 2012;46:716–23.PubMedCrossRef Herrschaft H, Nacu A, Likhachev S, et al. Ginkgo biloba extract EGb 761(R) in dementia with neuropsychiatric features: a randomised, placebo-controlled trial to confirm the efficacy and safety of a daily dose of 240 mg. J Psychiatr Res. 2012;46:716–23.PubMedCrossRef
65.
Zurück zum Zitat Ihl R, Bachinskaya N, Korczyn AD, et al. Efficacy and safety of a once-daily formulation of Ginkgo biloba extract EGb 761 in dementia with neuropsychiatric features: a randomized controlled trial. Int J Geriatr Psychiatry. 2011;26:1186–94.PubMed Ihl R, Bachinskaya N, Korczyn AD, et al. Efficacy and safety of a once-daily formulation of Ginkgo biloba extract EGb 761 in dementia with neuropsychiatric features: a randomized controlled trial. Int J Geriatr Psychiatry. 2011;26:1186–94.PubMed
66.
Zurück zum Zitat Napryeyenko O, Borzenko I;Gindem-Np Study Group. Ginkgo biloba special extract in dementia with neuropsychiatric features.A randomised, placebo-controlled, double-blind clinical trial. Arzneimittelforschung. 2007;57:4–11.PubMed Napryeyenko O, Borzenko I;Gindem-Np Study Group. Ginkgo biloba special extract in dementia with neuropsychiatric features.A randomised, placebo-controlled, double-blind clinical trial. Arzneimittelforschung. 2007;57:4–11.PubMed
67.
Zurück zum Zitat Nikolova G, Yancheva S, Raychev I, et al. Gingo biloba extract in dementia: a 22-week randomised, placebo-controlled, double-blind trial. Bulg Neurol. 2013;14:139–43. Nikolova G, Yancheva S, Raychev I, et al. Gingo biloba extract in dementia: a 22-week randomised, placebo-controlled, double-blind trial. Bulg Neurol. 2013;14:139–43.
68.
Zurück zum Zitat Schneider G, Heuft G. Angst und Depression beiälteren Menschen. Z Psychosomatische Med Psychother. 2012;58:336–56. Schneider G, Heuft G. Angst und Depression beiälteren Menschen. Z Psychosomatische Med Psychother. 2012;58:336–56.
69.
Zurück zum Zitat Forsell Y, Jorm AF, von Strauss E, et al. Prevalence and correlates of depression in a population of nonagenarians. Br J Psychiatry. 1995;167:61–4.PubMedCrossRef Forsell Y, Jorm AF, von Strauss E, et al. Prevalence and correlates of depression in a population of nonagenarians. Br J Psychiatry. 1995;167:61–4.PubMedCrossRef
70.
Zurück zum Zitat Trindade E, Menon D, Topfer LA, et al. Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. Can Med Assoc J. 1998;159:1245–52. Trindade E, Menon D, Topfer LA, et al. Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. Can Med Assoc J. 1998;159:1245–52.
71.
Zurück zum Zitat Montgomery SA. A meta-analysis of the efficacy and tolerability of paroxetine versus tricyclic antidepressants in the treatment of major depression. Int Clin Psychopharmacol. 2001;16:169–78.PubMedCrossRef Montgomery SA. A meta-analysis of the efficacy and tolerability of paroxetine versus tricyclic antidepressants in the treatment of major depression. Int Clin Psychopharmacol. 2001;16:169–78.PubMedCrossRef
72.
73.
Zurück zum Zitat Lader MH. Limitations on the use of benzodiazepines in anxiety and insomnia: are they justified? Eur Neuropsychopharmacol. 1999;9(Suppl. 6):S399–405.PubMedCrossRef Lader MH. Limitations on the use of benzodiazepines in anxiety and insomnia: are they justified? Eur Neuropsychopharmacol. 1999;9(Suppl. 6):S399–405.PubMedCrossRef
74.
Zurück zum Zitat Buffett-Jerrott SE, Stewart SH. Cognitive and sedative effects of benzodiazepine use. Curr Pharm Des. 2002;8:45–58.PubMedCrossRef Buffett-Jerrott SE, Stewart SH. Cognitive and sedative effects of benzodiazepine use. Curr Pharm Des. 2002;8:45–58.PubMedCrossRef
75.
Zurück zum Zitat Green RC, Cupples LA, Kurz A, et al. Depression as a risk factor for Alzheimer disease: the MIRAGE Study. Arch Neurol. 2003;60:753–9.PubMedCrossRef Green RC, Cupples LA, Kurz A, et al. Depression as a risk factor for Alzheimer disease: the MIRAGE Study. Arch Neurol. 2003;60:753–9.PubMedCrossRef
76.
Zurück zum Zitat Muliyala KP, Varghese M. The complex relationship between depression and dementia. Ann Indian Acad Neurol. 2010;13:S69–S73.PubMedCentralPubMed Muliyala KP, Varghese M. The complex relationship between depression and dementia. Ann Indian Acad Neurol. 2010;13:S69–S73.PubMedCentralPubMed
77.
79.
Zurück zum Zitat Licht-Strunk E, Van Marwijk HW, Hoekstra T, et al. Outcome of depression in later life in primary care: longitudinal cohort study with three years’ follow-up. BMJ. 2009;338:a3079.PubMedCentralPubMedCrossRef Licht-Strunk E, Van Marwijk HW, Hoekstra T, et al. Outcome of depression in later life in primary care: longitudinal cohort study with three years’ follow-up. BMJ. 2009;338:a3079.PubMedCentralPubMedCrossRef
80.
Zurück zum Zitat Nutt D, Allgulander C, Lecrubier Y, et al. Establishing non-inferiority in treatment trials in psychiatry: guidelines from an Expert Consensus Meeting. J Psychopharmacol. 2008;22:409–16.PubMedCrossRef Nutt D, Allgulander C, Lecrubier Y, et al. Establishing non-inferiority in treatment trials in psychiatry: guidelines from an Expert Consensus Meeting. J Psychopharmacol. 2008;22:409–16.PubMedCrossRef
81.
Zurück zum Zitat Masson SC, Tejani AM. Minimum clinically important differences identified for commonly used depression rating scales. J Clin Epidemiol. 2013;66:805–7.PubMedCrossRef Masson SC, Tejani AM. Minimum clinically important differences identified for commonly used depression rating scales. J Clin Epidemiol. 2013;66:805–7.PubMedCrossRef
82.
Zurück zum Zitat Furukawa TA, Akechi T, Azuma H, et al. Evidence-based guidelines for interpretation of the Hamilton rating scale for depression. J Clin Psychopharmacol. 2007;27:531–4.PubMedCrossRef Furukawa TA, Akechi T, Azuma H, et al. Evidence-based guidelines for interpretation of the Hamilton rating scale for depression. J Clin Psychopharmacol. 2007;27:531–4.PubMedCrossRef
83.
Zurück zum Zitat Kim YS, Nibbelink DW, Overall JE. Factor structure and scoring of the SKT test battery. J Clin Psychol. 1993;49:61–71.PubMedCrossRef Kim YS, Nibbelink DW, Overall JE. Factor structure and scoring of the SKT test battery. J Clin Psychol. 1993;49:61–71.PubMedCrossRef
84.
Zurück zum Zitat Ihl R, Grass-Kapanke B, Lahrem P, et al. Entwicklung und Validierungeines Tests zur Früherkennung der Demenz mit Depressionsabgrenzung (TFDD). Fortschr Neurol Psychiatr. 2000;68:413–22.PubMedCrossRef Ihl R, Grass-Kapanke B, Lahrem P, et al. Entwicklung und Validierungeines Tests zur Früherkennung der Demenz mit Depressionsabgrenzung (TFDD). Fortschr Neurol Psychiatr. 2000;68:413–22.PubMedCrossRef
85.
Zurück zum Zitat Sunderland T, Hill JL, Mellow AM, et al. Clock drawing in Alzheimer’s disease. A novel measure of dementia severity. J Am Geriatr Soc. 1989;37:725–9.PubMedCrossRef Sunderland T, Hill JL, Mellow AM, et al. Clock drawing in Alzheimer’s disease. A novel measure of dementia severity. J Am Geriatr Soc. 1989;37:725–9.PubMedCrossRef
Metadaten
Titel
Phytopharmaceutical treatment of anxiety, depression, and dementia in the elderly: evidence from randomized, controlled clinical trials
verfasst von
O. Univ. Prof. Dr. h.c.mult. Dr.med. Siegfried Kasper
Publikationsdatum
01.06.2015
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift / Ausgabe 11-12/2015
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-015-0360-y

Weitere Artikel der Ausgabe 11-12/2015

Wiener Medizinische Wochenschrift 11-12/2015 Zur Ausgabe